Company intelligence / Profile preview

Morphimmune

Seattle, Washington, United States

Ownership: Public · IMNM
Employees: ~2
Development stage: Other

Overview

Prior to acquisition, Morphimmune had two lead preclinical programs: a folate receptor-targeted TLR7 agonist (Mi-1001) and a FAP-targeted radioligand (177Lu-FAP). Both were positioned for IND-enabling studies, with the IND for Mi-1001 expected in late 2024 and 177Lu-FAP in early 2025. Clinical results are not yet available as all programs were pre-IND at time of merger[1][4][5].

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceuticalAntibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

AbbVie (via Immunome after merger)[1]

Beyond the preview

Go deeper on Morphimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphimmune.

Explore the full profile